These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36434435)

  • 1. Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT.
    Sun H; Yan H; Yan Z; Zhu Y; Yang G; Zhang S
    Ann Hematol; 2023 Feb; 102(2):473-475. PubMed ID: 36434435
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.
    Wen X; Wu Y; Huang P; Zheng H
    Pediatr Blood Cancer; 2023 Jul; 70(7):e30308. PubMed ID: 36965174
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
    Mitani Y; Hiwatari M; Seki M; Hangai M; Takita J
    Int J Hematol; 2019 Oct; 110(4):512-516. PubMed ID: 31134509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.
    Abematsu T; Nishikawa T; Shiba N; Iijima-Yamashita Y; Inaba Y; Takahashi Y; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29216. PubMed ID: 34245496
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
    Akiki S; Dyer SA; Grimwade D; Ivey A; Abou-Zeid N; Borrow J; Jeffries S; Caddick J; Newell H; Begum S; Tawana K; Mason J; Velangi M; Griffiths M
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1053-64. PubMed ID: 23999921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of monitoring NUP98::NSD1 fusion genes before and after allogeneic hematopoietic stem cell transplantation].
    Shang YK; Pan XA; Chang YJ; Qin YQ; Wang Y; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1010-1015. PubMed ID: 38503524
    [No Abstract]   [Full Text] [Related]  

  • 8. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
    Thanasopoulou A; Tzankov A; Schwaller J
    Haematologica; 2014 Sep; 99(9):1465-71. PubMed ID: 24951466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
    Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
    Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
    Shiba N; Ohki K; Kobayashi T; Hara Y; Yamato G; Tanoshima R; Ichikawa H; Tomizawa D; Park MJ; Shimada A; Sotomatsu M; Arakawa H; Horibe K; Adachi S; Taga T; Tawa A; Hayashi Y
    Br J Haematol; 2016 Feb; 172(4):581-91. PubMed ID: 26684393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.
    Matsukawa T; Yin M; Nigam N; Negi V; Li L; Small D; Zhu YJ; Walker RL; Meltzer PS; Aplan PD
    Leukemia; 2023 Jul; 37(7):1545-1548. PubMed ID: 37147424
    [No Abstract]   [Full Text] [Related]  

  • 12. Refractory pediatric acute myeloid leukemia expressing NUP98-NSD1 fusion gene responsive to chemotherapy combined with venetoclax and decitabine.
    Xu H; Yu H; Xu J; Zhou F; Tang S; Feng X; Luo Q; Zhang B; Wu X; Jin R; Chen H
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30021. PubMed ID: 36184746
    [No Abstract]   [Full Text] [Related]  

  • 13. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM
    Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive Minimal Residual Disease of FLT3-ITD before Hematopoietic Stem Cell Transplantation Resulted in a Poor Prognosis of an Acute Myeloid Leukemia.
    Iwasaki Y; Nishiuchi R; Aoe M; Takahashi T; Watanabe H; Tokorotani C; Kikkawa K; Shimada A
    Acta Med Okayama; 2017 Feb; 71(1):79-83. PubMed ID: 28238014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular Characteristics and Clinical Features of Adults with
    Lun Y; Huang JC; Long D; Wang FF; Dai Y; Yang Y; Zhao TT; Li Q; Wu Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):575-581. PubMed ID: 30378313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
    Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
    Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells.
    Okamoto K; Imamura T; Tanaka S; Urata T; Yoshida H; Shiba N; Iehara T
    Int J Hematol; 2023 Aug; 118(2):277-287. PubMed ID: 37173550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
    Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
    Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.
    Schiller GJ; Tuttle P; Desai P
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):982-990. PubMed ID: 26785334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.